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Pulmonary arterial hypertension (PAH) occurs with several rheumatologic diseases, however, it
is rarely reported with Adult-onset Still’s disease (AOSD). Pulmonary arterial hypertension is
a major cause of morbidity and mortality. We describe a patient with AOSD who developed
the characteristic clinical and hemodynamic findings of idiopathic PAH with persistent hypox-
emia. A remission was obtained with immunosuppressive treatment without addition of pros-
taglandins, endothelin antagonists or phosphodiesterase 5 inhibitors.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Adult-onset Still’s disease (AOSD) is a rare adult variant of
systemic juvenile rheumatoid arthritis. AOSD is characterized
by an acute febrile syndrome that affects multiple organs.
The diagnosis is one of clinical suspicion, requiring the
exclusion of infection, malignancy, and systemic disease.1
The condition is usually characterized by spiking fever,5 (47) 33228487/91876600;
hoo.com.br (M.E.Menezesde
ll rights reserved.maculopapular rash, sore throat, polyarthralgia, arthritis,
lymphadenopathy, hepatosplenomegaly and serositis. AOSD
has no specific laboratory criteria, but is common to find
leukocytosis, thrombocytosis and elevated acute-phase
reactants inAOSDpatients.2 Cardiopulmonarymanifestations
include pneumonitis, pleuritis, and pericarditis with effu-
sions, which rarely progress to acute respiratory distress,
pericardial tamponade and myocarditis. Pleuritis and peri-
carditis are quite common when detected as a result of
pleuritic chest pain, an auscultatory rub, or the demonstra-
tion of pleural or pericardial fluid by abnormal chest radio-
graphs, ultrasonography or echocardiogram.3 Pulmonary
arterial hypertension (PAH) is a major cause of morbidity and
mortality in connective tissue diseases. The pathogenesis of
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Immune and inflammatory mechanisms could play a role in
PAH pathogenesis in these patients.4 Pulmonary arterial
hypertension is rarely described with AOSD and, to our
knowledge, just three cases have been reported.4e6 Treat-
ment of AOSD is empirical in the absence of randomized trials
because of the rarity of the disease. Non-steroidal anti-
inflammatory drugs are rarely sufficient, and almost all AOSD
patients require corticosteroids.3 Here, we describe a patient
with AOSD who developed the characteristic clinical and
hemodynamic findings of idiopathic PAH with persistent
hypoxemia. The patient had an excellent response after
treatment for AOSD, with remission of PAH.Case report
An 18-year-old man was brought to us with a history of high
spiking fever, weight loss, polyarthralgia, andmaculopapular
rash, where all the symptoms had been present for 20 days.
He was previously healthy. He denied tobacco, alcohol, or
illegitimate drug or weight loss drug use. The patient was
being treated for community-acquired pneumonia with lev-
ofloxacin. Onexamination, he was febrile (39 C), hada pulse
of 100 beats/min, a respiration rate of 30 min1, and a blood
pressure of 128/87 mmHg. The chest was clear on ausculta-
tion. There was no synovitis, hepatosplenomegaly, scle-
rodactyly, lymphadenopathy, calcinosis or skin tightness,
and his body mass index was 35. Laboratory investigation
showed a total leukocyte count of 32,600 p/mm3, a hemo-
globin level of 10.2 g%, a platelet count of 200,000 p/mm3,
an ESR of 58 mm/1st h, a ferritin level of 2000 ng/ml,
a prothrombin time of 12 s, an INR of 1, an aspartate
aminotransferase level of 85 IU/L, an alanine aminotrans-
ferase level of 64 IU/L, and a lactate dehydrogenase level of
1081 IU/L. Serology tests for hepatitis B and C, EpsteineBarr
virus and human immunodeficiency virus were negative. The
results of urinalysis, stool analysis and blood culture were
normal. Rheumatoid factors, ASO, antinuclear antibody, and
antiphospholipid antibody were also negative. An abdominal
ultrasound was normal. After the exclusion of infection,
malignancy, and systemic disease, the diagnosis of AOSD was
suggested. After four days, the patient began complaining of
pleuritic chest pain and progressive exertional dyspnea. The
oxygen saturation with supplementary oxygen was 90%. The
arterial blood gas analysis revealed hypoxemia (PO2
65 mmHg) and hyperventilation (PCO2 28 mmHg). A ventila-
tion perfusion scintigraphy and computed tomogram of the
chest were negative for pulmonary embolism. There was no
evidence of pleural or parenchymal involvement of the lung,
pulmonary vasculitis, or immune deposition in the pulmonary
vasculature. Spirometry suggested mild restrictive lung
disease probably due to obesity [FVC 74% (4.36 L), FEV1 77%
(3.78 L), VEF1/FVC 103% (0.84 L)]. The diffusing capacity for
carbon monoxide was 62% (7.52 mM/min/KPa) with low
reduction. A transesophageal Doppler echocardiogram
showed no vegetation and intact interatrial and interven-
tricular septa. A right heart catheterization confirmed the
presence of pulmonary hypertension, with a main pulmonary
artery pressure of 58/10 mmHg, but normal capillary wedge
pressure of 9 mmHg. The patient was classified as NYHA class
III. He was treated with indomethacin, prednisone (60 mg/day) and methotrexate (20 mg/week). The heart catheteri-
zation was repeated after 6 months of treatment; the main
pulmonary artery pressure was 35/06 mmHg with a capillary
wedge pressure of 6 mmHg. The patient had no more
symptoms. A regression of the PAH was obtained with
immunosuppressive treatment without addition of prosta-
glandins, endothelin antagonists or phosphodiesterase 5
inhibitors.Discussion
We have reported a case of an 18-year-old man who was
diagnosed with AOSD and presented with PAH. The patient’s
pulmonary pressure was increased at rest (58/10 mmHg). His
normal pulmonary artery wedge pressure excluded signifi-
cant left ventricular dysfunction as a cause for the PAH. The
echocardiogram showed no valvular or congenital heart
disease. In the history, the patient had denied sleep-related
breathing problems or the use of anorexigens. Viral serol-
ogies and anti-HIV were negative. Liver cirrhosis and portal
hypertension could be excluded by the results of the
abdominal ultrasound scan. Ventilation perfusion scintig-
raphy revealed no central chronic pulmonary thromboemboli
and there were no defects apparent on the perfusion lung
scan. The lung parenchyma appeared normal on chest CT,
excluding interstitial lung disease as a cause of the patient’s
PAH. In patients with connective tissue diseases, PAH may
occur in association with interstitial fibrosis or as a result of
direct proliferative vascular involvement in the absence of
significant parenchymal disease or chronic hypoxia. The
pathophysiology is unknown, but the clinical course and
pathological findings are similar to primary pulmonary
hypertension. Several authors have hypothesized that
immunological disturbances promote the development of
pulmonary arteriopathy in these patients. A pulmonary
vasospasm, the so-called pulmonary Raynaud’s phenom-
enon, could hypothetically play a role. The presence of
antinuclear antibodies, rheumatoid factor, immunoglobulin-
G, and complement fraction deposits in the walls of pulmo-
nary vessels suggests a role for an immunological mecha-
nism.7 Scleroderma represents the main connective tissue
disease associated with PAH. Pulmonary hypertension also
occurs in other autoimmune rheumatic disease like systemic
lupus erythematosus, mixed connective tissue disease, der-
matomyositis, rheumatoid arthritis, Sjo¨gren’s syndrome and
antiphospholipid antibody syndrome.8,9 The prognosis is very
poor, and no curative treatment is available. In the absence
of major trials on pulmonary hypertension secondary to
connective tissue diseases, treatment should be conducted
in the same way as for idiopathic pulmonary hypertension.10
The difference is that immunosuppressive therapy may be
effective in only a few patients with pulmonary hypertension
secondary to connective tissue diseases. In the literature,
there are several reports describing regression of PAH during
treatment with corticosteroids associated with immunosup-
pressants in patients with rheumatologic diseases. Prospec-
tive studies are needed to confirm this clinical
observation.7,11 Our patient developed PAH with no apparent
parenchymal involvement; this was probably an inflamma-
tory pulmonary vasculopathy related to AOSD. After treat-
ment with glucocorticosteroids and indomethacin for AOSD,
72 M.E. Menezes de Siqueira et al.the patient showed improvement in the hemodynamic
parameters on right heart catheterization and NYHA func-
tional class. We describe, to our knowledge, the fourth case
of pulmonary hypertension complicating AOSD.
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